

Special Issue

New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health

Message from the Guest Editor

Antimicrobial resistance (AMR) is a serious cause of concern for public health. Difficult-to-treat pathogens are diffused worldwide, and related infections are associated to the important fatality rate. This Special Issue considers all aspects of infections related to difficult-to-treat pathogens and antimicrobial options. Articles or reviews regarding pan-drug- (PDR) or extensive drug-resistant (XDR) pathogens, metallo- β -lactamase (MBL)-producing Enterobacterales, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and vancomycin-resistant *Enterococcus* are encouraged.

Keywords: new antibiotics; new antimicrobial options; difficult-to-treat pathogens; emerging resistance; multidrug resistance; emerging virulence; *Acinetobacter baumannii*; *Pseudomonas aeruginosa*; metallo- β -lactamase-producing enterobacterales; vancomycin-resistant *Enterococcus*

Guest Editor

Dr. Luigi Principe

Microbiology and Virology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy

Deadline for manuscript submissions

closed (31 January 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/67865

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)